AU · rank #16 · 2026-10-22
IMCD
AMSTERDAM · EUR · $6.70B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.218 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.06 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +16.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +12.02% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $105.55 |
| Market cap (USD) | $6.70B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a global specialty chemical and ingredient distributor providing technical formulation, application laboratory, and regulatory support to chemical producers and downstream customers.
Rationale
Quant signals of 16.7% analyst upside and 100% positive 30-day EPS revision agreement are supported by a Q2 organic gross profit recovery (+7%) and 8% constant-currency H1 EBITA growth.
Material risks
- 1Disintermediation risk if primary chemical suppliers or large downstream customers build in-house technical sales and formulation capabilities.
- 2Gross margin compression from specialty chemical commoditization and elevated leverage (net debt at 2.8x operating EBITDA) amid bolt-on M&A.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.